Understand the source comparison
AOD-9604 5-Amino-1MQ Stack Fat Burning Without GLP-1 Protocol 2026: Dosing Comparison
Mechanism Beta-3 adrenergic receptor agonism → HSL activation → triglyceride hydrolysis NNMT inhibition → NAD+ preservation → enhanced mitochondrial fat oxidation GLP-1 receptor agonism → appetite suppression + delayed gastric emptying AOD-9604 and 5-Amino-1MQ
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism
- Beta-3 adrenergic receptor agonism → HSL activation → triglyceride hydrolysis
- NNMT inhibition → NAD+ preservation → enhanced mitochondrial fat oxidation
- GLP-1 receptor agonism → appetite suppression + delayed gastric emptying
- AOD-9604 and 5-Amino-1MQ target peripheral metabolic pathways without central appetite effects. Fundamentally different from GLP-1's hypothalamic mechanism
- Typical Research Dose
- 300–500 mcg/day subcutaneous
- 50–100 mg/day oral
- 1–2.4 mg/week (semaglutide)
- Lower absolute dosing frequency for peptide; oral bioavailability advantage for 5-Amino-1MQ
- Administration Route
- Subcutaneous injection (daily)
- Oral capsule (daily)
- Subcutaneous injection (weekly)
- GLP-1 requires less frequent injection but longer titration period
- Half-Life
- 8–10 hours
- 6–8 hours
- 5–7 days (GLP-1 agonists)
- Shorter half-lives require daily dosing but allow faster washout if adverse effects occur
- Primary Outcome
- Increased lipolysis without appetite suppression
- Enhanced fat oxidation through NAD+ availability
- 15–20% body weight reduction via caloric deficit
- GLP-1 produces larger absolute weight loss; stack produces metabolic efficiency gains
- GI Side Effects
- Minimal (not GI-mediated)
- 30–45% experience nausea during titration
- Stack avoids GI adverse events entirely. Major advantage for patients intolerant to GLP-1